Baron Cohen isn’t done railing against Zuckerberg, however. Yesterday, he tweeted in frustration, “We don’t let 1 person control the water for 2.5 billion people. We don’t let 1 person control electricity for 2.5 billion people. Why do we let 1 man control the information seen by 2.5 billion people? Facebook needs to be regulated by governments, not ruled by an emperor!
“SolveBio helps patients by making it possible to run diagnostic applications. Genetic diagnosis involves taking a person’s DNA and comparing it to the world’s information on the relationship between DNA and health,” said Kaganovich. “We provide that reference data in a simple, easy-to-use set of APIs. It’s ‘clinical-grade’ in that it is accurate, secure, up-to-date, and versioned (you know exactly what version of a dataset you are using).”
Esperion, which is based in Ann Arbor, Mich., said the drug’s brand name will be Nexletol. Esperion also has applied to the FDA for approval of a combination pill of bempedoic acid and ezetimibe, a non-statin pill approved in 2002. In studies, the combination pill reduced cholesterol by about 38 to 44 percent, depending on whether a person was taking a statin and how much, the company said. The FDA decision is expected shortly.